What is Sarepta Therapeutics, Inc.'s debt issuance proceeds?

Sarepta Therapeutics, Inc. (SRPT) reported debt issuance proceeds of $250M in Q1 2026.

What does debt issuance proceeds mean?

Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

Sarepta Therapeutics, Inc. SRPT Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Dyne Therapeutics, Inc.DYN

$49.45M—

Arrowhead ResearchARWR

$3.16M—

BioMarin PharmaceuticalsBMRN

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

See full

Market cap$1.76B-63.1%

Profitability

See full

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

See full

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromLinesOfCredit.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s debt issuance proceeds?: Sarepta Therapeutics, Inc. (SRPT) reported debt issuance proceeds of $250M in Q1 2026.
What does debt issuance proceeds mean?: Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.